Association between Neck Circumference and the Occurrence of Cardiovascular Events in Type 2 Diabetes: Beijing Community Diabetes Study 20 (BCDS-20)

Table 3

Baseline clinical characteristics in the cardiovascular group and the noncardiovascular group in women.

	Total ()	Non-CVD group ()	CVD group ()	t value	value
Age (years)	67.88 ± 9.64	67.77 ± 9.72	69.57 ± 8.20	−2.16	0.033
BMI (kg/m^2)	26.79 ± 57.28	26.86 ± 59.02	25.79 ± 3.50	0.73	0.466
Diabetic duration (years)	10.1 (6.8, 15.4)	10.0 (6.7, 15.3)	10.9 (8.0, 16.0)	1.75 (Z)	0.079
Smoking (n, %)	93 (5.13)	83 (4.86)	10 (9.43)	4.29 (x2)	0.038
WC (cm)	87.72 ± 9.64	87.59 ± 9.54	89.82 ± 10.95	−2.05	0.043
NC (cm)	35.26 ± 3.40	35.21 ± 3.38	36.07 ± 3.55	−2.53	0.012
SBP (mmHg)	129.41 ± 14.67	129.05 ± 14.40	135.18 ± 17.52	−3.53	0.001
DBP (mmHg)	76.94 ± 8.90	77.00 ± 8.64	76.01 ± 12.40	0.81	0.422
FPG (mmol/L)	7.78 ± 2.48	7.77 ± 2.50	7.86 ± 2.30	−0.35	0.724
HbA1c (%)	7.32 ± 1.54	7.30 ± 1.54	7.60 ± 1.50	−1.89	0.059
TG (mmol/L)	1.88 ± 1.24	1.87 ± 1.22	2.11 ± 1.58	−1.48	0.142
TC (mmol/L)	5.35 ± 1.24	5.33 ± 1.24	5.60 ± 1.16	−2.07	0.038
HDL (mmol/L)	1.38 ± 0.50	1.37 ± 0.46	1.45 ± 0.89	−0.84	0.404
LDL (mmol/L)	3.15 ± 0.95	3.14 ± 0.94	3.33 ± 1.00	−1.95	0.052
Antihypertension medication (n, %)	1136 (62.59)	1056 (61.79)	80 (75.47)	7.98 (x2)	0.005
Antiglycemic medication (n, %)	1660 (91.46)	1563 (91.46)	97 (91.51)	0.00 (x2)	0.985
Statin (n, %)	1218 (67.11)	1146 (67.06)	72 (67.92)	0.03 (x2)	0.854

Rank sum test was used, expressed as median (range). Chi-square was used. CVD, cardiovascular disease; BMI, body mass index; WC, waist circumference; NC, neck circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure; FPG, fasting plasma glucose; HbA1c, hemoglobin A1c; TG, triglyceride; TC, total cholesterol; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol.